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A multidimensional network approach reveals microRNAs as
determinants of the mesenchymal colorectal cancer subtype
E Fessler1,2, M Jansen3,9, F De Sousa E Melo1,2,10, L Zhao4, PR Prasetyanti1,2, H Rodermond1,2, R Kandimalla1,2, JF Linnekamp1,2,
M Franitza5,6, SR van Hooff1,2, JH de Jong1,2, SC Oppeneer7, CJM van Noesel3, E Dekker7, G Stassi8, X Wang4,11, JP Medema1,2,11
and L Vermeulen1,11
Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classiﬁcation and treatment of this malignancy.
There is no common genetic molecular feature that would allow for the identiﬁcation of patients at risk for developing recurrences
and thus selecting patients who would beneﬁt from more stringent therapies still poses a major clinical challenge. Recently, an
international multicenter consortium (CRC Subtyping Consortium) was established aiming at the classiﬁcation of CRC patients in
biologically homogeneous CRC subtypes. Four consensus molecular subtypes (CMSs) were identiﬁed, of which the mesenchymal
CMS4 presented with worse prognosis signifying the importance of identifying these patients. Despite the large number of samples
analyzed and their clear association with unifying biological programs and clinical features, single-driver mutations could not be
identiﬁed and patients are heterogeneous with regard to currently used clinical markers. We therefore set out to deﬁne the
regulatory mechanisms underlying the distinct gene expression proﬁles using a network-based approach involving multiple
molecular modalities such as gene expression, methylation levels and microRNA (miR) expression. The miR-200 family presented as
the most powerful determinant of CMS4-speciﬁc gene expression, tuning the majority of genes differentially expressed in the poor
prognosis subtype, including genes associated with the epithelial–mesenchymal transition program. Furthermore, our data show
that two epigenetic marks, namely the methylation of the two miR-200 promoter regions, can identify tumors belonging to the
mesenchymal subtype and is predictive of disease-free survival in CRC patients. Importantly, epigenetic silencing of the miR-200
family is also detected in epithelial CRC cell lines that belong to the mesenchymal CMS. We thus show that determining regulatory
networks is a powerful strategy to deﬁne drivers of distinct cancer subtypes, which possess the ability to identify subtype afﬁliation
and to shed light on biological behavior.
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INTRODUCTION
Colorectal cancer (CRC) is a heterogeneous disease, which until
recently has only been reﬂected by (i) histopathological classiﬁca-
tion, (ii) single molecular conditions such as microsatellite
instability (MSI) and (iii) mutation status of major cancer genes.
However, the diversity of the disease has made it difﬁcult to
accurately classify and treat CRC patients. Only lately, CRC patients
have been categorized using unsupervised classiﬁcation of gene
expression proﬁling which resulted in the identiﬁcation of distinct
CRC subtypes.1–6 In an effort to generate a uniﬁed classiﬁcation
system, the CRC Subtyping Consortium (CRCSC) was established,
which identiﬁed the existence of four consensus molecular
subtypes (CMSs) in a large panel of CRC patients (n= 4151).7
Different CMSs associate with speciﬁc molecular, biological and
clinical features and thus present distinct entities. Linking the
subtypes to disease outcome revealed that the mesenchymal
CMS4 displayed worse prognosis, highlighting the clinical
relevance of this approach.7
To date subtyping of CRC based on gene expression data has
not taken regulatory networks into account, thus the underlying
determinants remain elusive.8 In glioblastoma such a transcrip-
tional network driving the expression of mesenchymal genes of a
poor prognosis subtype was identiﬁed.9 Also in ovarian and gastric
carcinoma a poor prognosis mesenchymal subtype was detected,
driven by a microRNA (miR) regulatory network.10,11 miRs are short
noncoding RNAs that regulate translation of mRNAs into
proteins.12 Individual miRs can affect an extensive number of
genes simultaneously,13,14 explaining their ability to inﬂuence
expression of complete networks deﬁning a cancer subtype. Of
special interest with regard to driving poor prognosis subtypes is
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the ability of miRs to regulate the expression of genes associated
with aggressive features of malignancies, such as the epithelial–
mesenchymal transition (EMT).15 Cancer cells undergoing EMT
lose epithelial characteristics, such as polarity and cell–cell
adhesion, and gain mesenchymal features that allow them to
disseminate to distant organs.16 A direct link between miRs and
EMT was ﬁrmly established and speciﬁcally the miR-200 family has
been implicated in repressing the EMT-inducing zinc-ﬁnger E-box
binding homeobox transcription factors ZEB1 and ZEB2,17,18
thereby inhibiting the EMT program. Also in CRC miR-200 family
members have been shown to regulate the transition between
distinct cellular states,19 and to play a role in development of
metastatic disease. Cells at the invasive front of tumors down-
regulate miR-200 expression, allowing them to undergo EMT
and leave the primary tumor. This process is reversed in meta-
static lesions, leading to the re-acquisition of an epithelial
phenotype.20,21 The expression of miR-200 family members, and
thus the orchestration of the EMT program, has been shown to be
regulated by miR-200 promoter methylation.21–25
Herein, we describe a network-based approach enabling the
identiﬁcation of subtype-speciﬁc drivers to gain insight into the
molecular determinants of distinct CRC subtypes. The dominant
regulatory network identiﬁed in the CMS4 group consists of the
miR-200 family. Methylation of the miR-200 promoter regions
controls the activity of this network and is responsible for tuning
the gene expression of the poor prognosis CMS. We show that in
CRC the miR-200 family cannot only be used to deﬁne distinct
cellular states, such as associated with the EMT program, but
regulates subtype-speciﬁc gene expression, thus being a determi-
nant for the subset of poor prognosis, mesenchymal CRCs.
Deﬁning the underlying regulatory network of CMS4 tumors
allowed us to identify miR-200 promoter methylation as a
molecular marker that can be used to determine subtype
afﬁliation at early stages in tumor development and that presents
an independent prognostic factor in stage II CRC.
RESULTS
Gene expression proﬁling identiﬁes a heterogeneous group of
poor prognosis CRCs
Based on gene expression proﬁling, CRCs can be divided into four
main CMSs using a random forest classiﬁer.7 To illustrate this
ﬁnding, the classiﬁer was applied to a large publicly available data
set of 566 colon cancer patients (Cartes d’Identité des Tumeurs,
CIT) (Supplementary Figure S1a).6 A total of 557 patients were
classiﬁed in one of the four CMSs (Figures 1a and b). This gene
expression-based classiﬁcation allowed for the identiﬁcation of
distinct subsets of CRC. The largest CMS2 subgroup, for instance,
associated with the well-characterized chromosomal-instable (CIN)
type of CRC, as 95.5% of the tumors identiﬁed as CMS2 were CIN+
and mainly anatomically left-sided, displaying KRAS and/or TP53
mutations. The CMS1 group contained a high level of MSI and
CIMP+ right-sided tumors, therefore associating with the reported
MSI/CIMP+ type of CRC (Figure 1b).26–28 However, none of these
molecular markers was able to unequivocally point to one subtype
and especially tumors belonging to the CMS3 and CMS4 subtypes
represented heterogeneous groups of CRC patients with respect
to molecular aberrations commonly occurring in this disease
(Figure 1b). There was however a strong association of clinical
characteristics, as the CMS1–3 subgroups were enriched in stage I
+II tumors, whereas more than 55% of CMS4 tumors were
classiﬁed as stage III+IV (Figure 1b). Although representing a
mixed group based on molecular markers, we observed a
signiﬁcantly poorer prognosis for patients with CMS4 tumors
(Figure 1c). Therefore the clinical relevance of this approach was
conﬁrmed as it allows the identiﬁcation of a subtype with
signiﬁcantly decreased disease-free survival (DFS).
A microRNA regulatory network accounts for differential gene
expression between CMS1–3 and CMS4 tumors
Mutation status or molecular characteristics such as MSI do not
allow the distinction between the different CMSs, indicating that
the driving force for speciﬁc cancer subtypes is more complex.
To investigate which regulatory network is predominantly
responsible for differences in gene expression between the
subtypes we generated three regulatory networks comprising
various dimensions of molecular regulation. In particular we
studied (i) transcription factors (TFs) (Supplementary Figure S2),
(ii) methylation marks (Supplementary Figure S3) and
(iii) microRNAs (miRs) (Figure 2) as putative subtype-speciﬁc
regulators. Network analyses were performed to identify which
level of regulation was most stringently associated with the
subtype-speciﬁc gene expression distinction in the TCGA data set
(Supplementary Figure S1a). We chose to investigate the differences
between CMS1–3 and CMS4 tumors, as this mesenchymal subtype is
associated with worse clinical outcome. The miR network, consisting
of miRs signiﬁcantly lower expressed in CMS4 compared with
CMS1–3 tumors (Supplementary Figure S4a), was found to be the
most powerful determinant of subtype-speciﬁc regulation of gene
expression. The largest regulatory element was predicted to be
responsible for 74.8% of the variation in gene expression
(Supplementary Figure S4b; based on reference networks; for
comparisons with the other networks the percentage was calculated
based on the transcriptional network with redundant edges
removed based on ARACNE which resulted in a percentage of
61.9%). The largest elements in the TF- and methylation mark-based
regulatory networks account for approximately 10.3 and 10.4%,
respectively. The dominant regulatory element in the miR network
was generated by the miR-200 family, namely miR-200a, miR-200b,
miR-200c, miR-141 and miR-429, representing miRs whose
expression levels differ signiﬁcantly between CMS1–3 and CMS4
tumors (Supplementary Figure S5a). The network analysis
predicted that these miRs target similar genes, suggesting that
the miR-200 family members are functionally related, which was
conﬁrmed by analyzing the overlap of genes most strongly
predicted (Po0.01) to be regulated by one of the miR-200 family
members based on the network analysis (Supplementary
Figure S5b).
These ﬁndings point to a critical role of the miR-200 regulatory
network in orchestrating subtype-speciﬁc gene expression. As
reported before, expression of the miR-200 family associated with
low expression of mesenchymal genes and inhibition of the EMT
program by modulating ZEB1 levels,17,18,29,30 thus the low
abundance of mi-200 family members in CMS4 tumors could
explain their mesenchymal phenotype.
Highlighting the genes belonging to an experimentally derived
EMT signature in the inferred regulatory network revealed that
many of the EMT-associated genes were indeed predicted to be
regulated by the identiﬁed miRs (Figure 2).31 Most of the EMT
genes belonged to the miR-200 family cluster, and reversely,
further analysis revealed that 12 miRs, including all miR-200 family
members, function as master regulators of the EMT signature
(Supplementary Figure S4c). Consistent with the idea that miR-200
members are instrumental in orchestrating an EMT signature in
CMS4 tumors, the expression of genes present in an experimen-
tally derived EMT signature was highly enriched in CMS4 tumors
of the CIT data set (Supplementary Figure S6).6,31
Methylation of promoter regions underlies differential expression
of miR-200 family members
The members of the miR-200 family are organized as polycistronic
transcripts on chromosome 1 (miR-200ba429) and chromosome
12 (miR-200c141).32 The methylation mark regulator network
identiﬁed the methylation of the miR-200 loci as regulator of
subtype-speciﬁc gene expression (Supplementary Figure S3) and
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promoter methylation has been described to regulate expression
of miR-200 family members.22–25 Indeed, both miR-200 loci
displayed signiﬁcantly higher methylation levels in CMS4 CRC
samples from the TCGA set (Figure 3a). The methylation of the two
loci was highly correlated, conﬁrming the role of all miR-200 family
members in regulating a common gene expression program
(Figure 3b). Furthermore, methylation of each locus signiﬁcantly
correlated with expression of the respective miR-200 family
member (Figure 3c and Supplementary Figures S5c–e), suggesting
it to be decisive for the differential miR-200 expression.
Additionally the EMT-inducing TF ZEB1, which is a direct target
of the miR-200 family,30 was signiﬁcantly higher expressed in
tumors belonging to the CMS4 group (Figure 3d).
Recently, two independent studies reported that not the
epithelium, but the abundance or activation of the stroma
accounts for the mesenchymal status of this CRC subtype.33,34
As miR-200 family expression is suggested to be regulated by
methylation in stromal ﬁbroblasts as well,25 the elevated levels of
methylation could therefore simply reﬂect the amount of stroma
in these tumors. However, our data point to the expression of
ZEB1 in the epithelium of mesenchymal tumors,2 suggesting that
this mechanism of gene regulation is active in the malignant,
epithelial part of CMS4 tumors. Indeed, the analysis of primary
tumors and cell lines or xenografts derived from these cancers
conﬁrmed this observation (Supplementary Figure S8). In primary
tumors, whose corresponding cell lines or xenografts do not
Figure 1. Classiﬁcation of CRC samples into four distinct subtypes based on gene expression. (a) In total, 557 patients of the CIT data set are
classiﬁed in four CMSs. Columns indicate patients, whose subtypes are indicated in the top bar. The posterior probability of belonging to the
subtype is shown in the bar below the heatmap. Rows represent genes of a random forest classiﬁer. The heatmap displays the median
centered log2 gene expression levels (high expression: orange, low expression: blue). (b) Association of each subtype with molecular
characteristics as well as stage and tumor location. The number of patients displaying the respective characteristic and the total number of
patients analyzed are shown. The percentage of positivity is shown in brackets. Asterisks indicate the signiﬁcance of association of one
subtype with the respective feature as determined by hypergeometric tests (**Po0.01, ***Po0.001). (c) KM curve showing DFS of patients of
the CIT set according to CMS. P-value is based on log-rank test.
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display any miR-200 promoter methylation, this signal probably
reﬂects the stromal content of these cancers. Yet, if miR-200
promoter methylation displays high levels in the primary tumors,
it can also be detected in matching cell lines and xenografts,
therefore methylation signals derived from the epithelial tumor
cell fraction importantly contribute to this signal (Supplementary
Figure S8). To study miR-200 promoter methylation in the
epithelial compartment more closely we made use of CRC cell
lines stratiﬁed into the CMSs using gene expression data. Also in
this in vitro culture system, we could detect methylation of the
miR-200 promoter regions. Seventy-one percent of cell lines
classiﬁed as CMS4 (5/7) presented with high miR-200 promoter
methylation levels, whereas only one CMS1 cell line (14%) and
none of the cell lines classiﬁed as CMS2 and CMS3 displayed these
methylation marks (Figure 4a and Supplementary Figure S7). The
highest levels of miR-200 promoter methylation were detected in
cell lines that also displayed low levels of miR-200 expression
(Figure 4b). Using decitabine the miR-200 loci were demethylated in
two cell lines belonging to the mesenchymal subtype, which
resulted in the upregulation of miR-200 family member expression
(Figure 4c). Interfering with another component of epigenetic gene
regulation, namely acetylation, by histone deacetylase inhibition
using Panobinostat, did not modulate miR-200 family expression in
a meaningful and consistent way (Supplementary Figure S9). These
results indicate that repression of the miR-200 regulatory network
by methylation is instrumental in controlling miR-200 expression
and is indeed active in the epithelial compartment of CMS4 tumors.
miR-200 family members are instrumental for subtype-associated
gene expression
To conﬁrm the role of miR-200 family members in regulating
subtype-speciﬁc gene expression, miR-200 family members were
introduced in three CMS4 cell lines resulting in high levels of
Figure 2. Network analysis identiﬁes the miR-200 family as the main regulatory network of CMS4- and EMT-related genes. Displayed is the
differential miR expression between CMS1–3 and CMS4 tumors of the TCGA data set (green: lowly expressed in CMS4). Genes predicted to be
regulated by the miRs are shown based on their differential expression between CMS1–3 and CMS4 tumors (blue: lowly expressed in CMS4,
orange: highly expressed in CMS4). The connection between miRs and genes is depicted in red (induction) or blue (repression) based on the
inﬂuence of the miR on gene expression. EMT-associated genes from the Taube EMT signature are highlighted as rectangles.
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miR-200 family member expression, downregulation of ZEB1 and
upregulation of E-Cadherin (Figure 5a and Supplementary
Figure S10a). Gene expression proﬁles were derived from these
lines and gene set enrichment analysis35,36 revealed that genes
that were putatively regulated by miR-200 family members, that is,
the miR-200 family regulon in the network analysis, were
signiﬁcantly enriched in the gene set that is regulated by
miR-200 expression (Supplementary Figure S10b). Moreover,
miR-200 overexpression in cell lines suppressed EMT-associated
genes (Figure 5b) and genes involved in matrix remodeling,
migration and transforming growth factor-β signaling
(Supplementary Figures S10c–e). Importantly, genes upregulated
in CMS4 compared with CMS1–3 tumors were signiﬁcantly
inhibited in the miR-200-overexpressing cell lines (Figure 5c). To
assess whether overexpression of miR-200 family members also
has a functional impact, we introduced the two clusters into the
primary colon cancer cell line RC511 (Supplementary Figure S11a).
RC511 cells show high methylation of miR-200 promoter regions
(Supplementary Figure S8) and classify as CMS4 based on
gene expression (data not shown). Overexpression of miR-200
family members resulted in similar gene expression changes as
observed in the above-mentioned cell lines: the EMT-inducing
TF ZEB1 was downregulated and E-Cadherin expression was
induced (Supplementary Figure S11b). Subcutaneous injection of
RC511 cells into NSG mice revealed that overexpression of
miR-200 family members renders the cells less aggressive,
evidenced by slower tumor growth (Supplementary Figure S11c)
and longer survival time (Supplementary Figure S11d). In
combination, these ﬁndings validate the notion that the miR-200
family represents an important determinant of subtype-speciﬁc
gene expression and functional properties.
Methylation of the miR-200 loci is a determinant of CMS4
afﬁliation and is predictive of DFS
As miR-200 family members orchestrate subtype-speciﬁc gene
expression, we speculated that the methylation of the miR-200
loci is a predictor of disease subtype and in consequence
identiﬁes patients with poor prognosis. We computed a binary
logistic regression model using both miR-200 loci methylation
levels as covariates. The resulting predicted probabilities were
used to calculate the receiver operator characteristics curve,
revealing that miR-200 loci methylation was indeed able to
identify CMS4 afﬁliation in the TCGA data set (Figure 6a). Next, we
sought to validate the utility of this test in an independent patient
series. We therefore determined the methylation of the miR-200
promoter regions in the AMC-AJCCII-90 data set comprising only
stage II CRC patients (Supplementary Figures S1a and b). Tumors
of the CMS4 group showed a signiﬁcantly higher methylation of
the miR-200 loci compared with tumors belonging to the other
subtypes (Figure 6b). The methylation of these two loci was highly
correlated (Figure 6c); however, the methylation levels were not
inﬂuenced by the CIMP status of the tumor (Figure 6d), indicating
that it is not a feature of tumors with overall higher DNA
Figure 3. miR-200 loci are highly methylated in tumors of the mesenchymal CMS4. (a) Relative methylation of the miR-200ba429 and
miR-200c141 loci in CMS1–4 tumor samples of the TCGA data set. For each sample the methylation of the two or three miRs belonging to one
locus is averaged. Boxes extend from the 25th to the 75th percentile; the lines indicate the median. The whiskers are drawn to the 5th and the
95th percentile, outliers are depicted as dots. (n= 32 for CMS1, n= 66 for CMS2, n= 35 for CMS3, and n= 61 for CMS4. **Po0.01, ***Po0.001,
asterisks indicate the signiﬁcance of the respective subtype compared with CMS4; P-values are based on two-tailed Student’s t-tests). (b) The
methylation of the miR-200ba429 and miR-200c141 loci is highly correlated. (c)The methylation of the miR-200ba429 locus is highly correlated
with the expression of miR-200b and the methylation of the miR-200c141 locus with the expression of miR-200c. (d) CMS4 tumors display
signiﬁcantly higher expression of ZEB1 compared with CMS1–3 tumor samples (***Po0.001, asterisks indicate the signiﬁcance of the
respective subtype compared with CMS4; P-values are based on two-tailed Student’s t-tests. Box plots represent the same parameters as
described in (a)).
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Figure 4. CMS4 cell lines often display high miR-200 promoter methylation levels, which are instrumental for miR-200 repression. (a) Promoter
methylation levels of miR-200 family members in CMS1–4 CRC cell lines (**Po0.01, asterisks indicate the signiﬁcance of the respective
subtype compared with CMS4; P-values are based on two-tailed Student’s t-tests; n= 7 for CMS1, n= 12 for CMS2, n= 3 for CMS3, n= 7 for
CMS4. Boxes extend from the 25th to the 75th percentile and the lines indicate the median. The whiskers and outliers are plotted using the
Tukey method). (b) Cell lines that display high miR-200 promoter methylation (410%) express low levels of the miR-200 family members
(n= 38 for methylation o10% and n= 6 for methylation410%; *Po0.05, **Po0.01; P-values are based on two-tailed Student’s t-tests. Boxes
extend from the 25th to the 75th percentile and the lines indicate the median. The whiskers are drawn to the 5th and the 95th percentile,
outliers are depicted as dots. (c) Decitabine (DAC) treatment of the HUTU-80 and MDST8 cell lines reveals that a reduction in methylation
results in re-expression of the miR-200 family members (n= 3, P-values are based on two-tailed Student’s t-tests, *Po0.05, **Po0.01,
***Po0.001).
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methylation, but that these regions are speciﬁcally methylated.
DNA methylation in the patients displayed a gradient for both loci,
in which CMS4 samples were enriched in the quartile displaying
the highest DNA methylation (Supplementary Figures S12a and b).
Also in this data set, the combined methylation of the miR-200 loci
was able to predict CMS4 afﬁliation with high conﬁdence
(Figure 6e).
Because detection of stage II CRC patients that harbor a poor
prognosis is of utmost importance as this provides the opportu-
nity to treat these patients with adjuvant therapy, we investigated
if miR-200 methylation directly predicts patient prognosis.
DFS data are available for all patients of the AMC-AJCCII-90 set,
in which disease recurrence largely represents detection of
metastases in the liver, the lung or the peritoneal cavity.
miR-200 promoter methylation was able to identify patients
developing recurrences using a Cox proportional hazards regres-
sion model (Figure 7a). A Kaplan–Meier (KM) curve was generated
making use of a cutoff determined using this receiver operator
characteristics curve. Indeed patients containing highly methy-
lated tumors displayed a signiﬁcantly poorer DFS compared with
patients whose tumors showed lower methylation of the miR-200
loci (Figure 7b). To exclude that the miR-200-based stratiﬁcation
leads to a separation of MSI samples that are known to have a
better prognosis, the above-described analyses were performed
using only microsatellite stable (MSS) patients of the TCGA and
AMC-AJCCII-90 data sets, resulting in similar outcomes
(Supplementary Figure S13).
Multivariate analyses conﬁrmed that miR-200 promoter
methylation is an independent prognostic factor (P= 0.002) in
the AMC-AJCCII-90 data set also when taking T-stage, differentia-
tion grade, MSS/MSI and BRAF mutation status into account
(Figure 7c). Hence, we identiﬁed the miR-200 promoter methyla-
tion as a critical molecular determinant of the mesenchymal CMS,
therefore strongly correlating with the patient group that is at
high risk for developing recurrences.
DISCUSSION
Gene expression proﬁling is a powerful tool to detect different
patient subgroups and four distinct CRC CMSs have been
identiﬁed in a large international multicenter study.7 Tumors
belonging to the different CMSs present distinct entities
characterized by unifying biological programs and speciﬁc survival
rates. Yet, it is not clear whether there is a common underlying
mechanism for differences in gene expression or distinct clinical
outcome. Herein, a network-based approach was applied to
investigate the drivers of speciﬁc CRC subgroups. Making use of
the TCGA data set, we studied gene expression regulation on
several dimensions, such as methylation and miRs. As CMS4
tumors display worse prognosis and are thus in need of early
identiﬁcation, we chose to validate our approach using the CMS1–
3 vs CMS4 distinction. This way, the miR-200 family was identiﬁed
as subtype determinant.
The idea of an aggressive mesenchymal CMS in which epithelial
cells gain malignant features by undergoing an EMT program has
recently been challenged. Two studies report that not the
epithelium, but the abundance or activation of the stroma causes
the mesenchymal appearance of CMS4 tumors.33,34 Indeed,
stromal cells display methylation of the miR-200 loci and thus
likely contribute to the observed miR-200 promoter methylation
levels in primary tumors.25 However, we demonstrate that this
epigenetic regulatory loop is also active in epithelial cells, as the
miR-200 promoter regions display high methylation levels in cell
lines mainly belonging to the CMS4 subtype. We speculate that a
shared, yet unidentiﬁed upstream mechanism is responsible for
Figure 5. miR-200 family members regulate EMT- and CMS4-associated genes. (a) ZEB1 expression is reduced and E-Cadherin expression
induced in two CMS4 cell lines following overexpression of miR-200ba429, miR-200c141 or the combination of both clusters, indicating an
overlap in target genes. (b, c) Gene set enrichment analysis (GSEA) of miR-200-overexpressing cell lines conﬁrms that these miRs signiﬁcantly
regulate (b) EMT-associated genes31 and (c) the CMS4-speciﬁc gene expression program (log2FC (CMS4 vs CMS1–3)40.85, FDRo0.001). ES,
enrichment score.
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EMT induction in tumor epithelial cells, as well as for attracting
abundant and activated mesenchymal cells to the cancer site.
The EMT is a process during which epithelial cells lose their cell–
cell junctions, and gain a mesenchymal, migratory and invasive
phenotype, allowing them to leave the primary site and spread to
distant organs.37 Indeed, EMT has been linked to dismal outcome
before.38,39 Two recent reports using mouse models enforce this
notion, yet link EMT to therapy resistance rather than enhanced
metastatic spread.40,41 Notwithstanding the exact mechanism, the
mesenchymal phenotype has been linked to poor prognosis in
patients for many cancer types, including CRC.7
As we describe here, the methylation of the miR-200 promoter
regions—an epigenetic modiﬁcation allowing for the activation of
the EMT program—could serve as a tool to identify poor
prognosis CRC lesions early on. This epigenetic mark is prognostic
in stage II CRCs and could be used to select individuals that are
likely to beneﬁt from more aggressive therapy. It remains to be
examined whether high methylation levels could also be used as a
marker to identify patients within this group that beneﬁt from
adjuvant therapy. In this regard, the simplicity and highly robust
nature of the miR-200 promoter methylation assay might be of
great beneﬁt to the ﬁeld as this will allow for improved
retrospective analysis of clinical studies and design of novel trials
aiming to improve therapeutic outcome in these patients.
Taken together, our data demonstrate that employing networks
to study subtype-speciﬁc gene expression is a powerful approach
to identify drivers of distinct cancer subgroups. The regulators
determined in this way grant insight into the biological behavior
of the subtype. Herein, we show that the miR-200 network is a
determinant for mesenchymal CRCs and that its activity is
regulated by promoter methylation. This methylation mark is
predictive of disease outcome, can be detected already early in
the development of CRC and thus presents a tool to identify poor
prognosis patients at early stages.
MATERIALS AND METHODS
Sample collection
Frozen tissues were collected from pathology (AMC), following the
institute’s guidelines (Medical Ethical Committee, AMC, Amsterdam, the
Netherlands). No approval was needed for samples of the AMC-AJCCII-90
data set; the material was collected as rest material in accordance with the
Dutch legislation.
Clinical characteristics of the AMC-AJCCII-90 data set, processing of
samples for microarray (GSE33113), gDNA extraction, bisulﬁte conversion
and CIMP analysis were described before.2
Consensus molecular subtype (CMS) classiﬁcation
CIT data set: microarrays (GSE39582) were ﬁrst normalized and summar-
ized using the robust multi-array average method. Non-biological effects
across batches were detected using principal component analysis and
Figure 6. miR-200 loci methylation is predictive of CMS4 afﬁliation in the TCGA and AMC-AJCCII-90 data sets. (a) The receiver operator
characteristics (ROC) curve showing the prediction of CMS4 afﬁliation in the TCGA data set using miR-200 loci methylation (AUC= area under
the curve). (b) The promoter methylation of the miR-200ba429 and the miR-200c141 loci of 80 patients of the AMC-AJCCII-90 set shows
signiﬁcantly higher levels in tumors of the CMS4 class (*Po0.05, ***Po0.001, asterisks indicate the signiﬁcance of the respective subtype
compared with CMS4; P-values are based on two-tailed Student’s t-tests. Boxes extend from the 25th to the 75th percentile, the lines indicate
the median. The whiskers are drawn to the 5th and the 95th percentile, outliers are depicted as dots; n= 20 for CMS1, n= 31 for CMS2, n= 9
for CMS3 and n= 20 for CMS4). (c) The methylation of the miR-200c141 and miR-200ba429 loci is highly correlated, (d) but is not inﬂuenced by
the CIMP status of the tumor. The average methylation of both miR-200 loci taken together is shown (box plots represent the same
parameters as described in (b)). (e) The ROC curve showing the prediction of CMS4 afﬁliation in the AMC-AJCCII-90 data set using miR-200 loci
methylation.
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were corrected using ComBat.42 The expression proﬁles were standardized
and then subjected to classiﬁcation using the CMS classiﬁer as described.7
Using the same strategy, we classiﬁed the Sanger CRC cell line panel
(n=43). This was performed using multiple publicly available gene
expression data sets ArrayExpress database (E-MTAB-783), the Cancer Cell
Line Encyclopedia43 (n= 55, GSE36133), Wagner et al.44 (n=38, GSE8332)
and Medico et al.45 (n=155, GSE59857). Additionally, we derived a classiﬁer
that was optimized by ﬁrst identifying epithelial-expressed genes and
subsequent training on the CIT data set. This epithelial-speciﬁc classiﬁer
was applied to the same data sets as described above. Using all data sets
and the different classiﬁcation methods revealed that most of the lines
were consistently classiﬁed. However, for some cell lines, this resulted in
different CMS afﬁliations. Cell lines that could not be classiﬁed with a
conﬁdence of 466.6% were excluded. Using this approach 29 cell lines
were faithfully classiﬁed.
Two independent TCGA RNASeq data sets, based on Illumina GA and
HiSeq platforms, were used for constructing a regulatory network and for
correlation analysis, respectively. CMS classiﬁcation for the two TCGA data
sets and the AMC-AJCCII-90 data set were obtained from the CRCSC.7
Regulatory network inference
We employed a network-based approach to study the regulatory
relationships between miRs and potential target genes. Gene
expression data are log2-transformed RPKM proﬁles (n = 270) in the
TCGA Illumina GA data set, while the miR data are log-transformed RPM
(reads per million miR mapped, n = 255) obtained from The Cancer
Genome Atlas Network.28 Together, 200 patient samples have both miR
and gene expression data. We focused on 30 miRs downregulated
(fold change o0.71, false discovery rate (FDR)o0.001) in CMS4 vs
CMS1–3, and 1437 genes differentially expressed between CMS4 and
CMS1–3 (|log2FC|40.85, FDRo0.001). The miR expression data and
gene expression data were standardized independently and merged for
network inference. The bioconductor RTN package was employed to
infer the regulatory network.
We tested the statistical signiﬁcance of overrepresentation of EMT
signature genes31 in each miR’s regulon. Twelve miRs of top signiﬁcance
(Benjamini–Hochberg-adjusted P-valueo0.05) were selected as master
regulators.
Inference of transcription factor regulatory network
From the total number of 1544 transcription factors (TFs) obtained from
AnimalTFDB,46 we ﬁrst selected 90 TFs signiﬁcantly differentially expressed
between CMS4 and CMS1–3 (|log2FC|40.85, FDRo0.001). The same
approach used for inference of the miR regulatory network was employed
here to infer a network encoding regulatory relationships between TFs and
target genes.
Figure 7. miR-200 loci methylation is predictive of prognosis in the AMC-AJCCII-90 data set. (a) The receiver operator characteristics (ROC)
curve displaying the survival prediction in the AMC-AJCCII-90 data set. Green lines indicate cutoff used for the KM curve shown in (b). (b) The
KM curve depicting DFS survival of the AMC-AJCCII-90 data set separated based on the cutoff chosen using the ROC curve shown in
(a) (P-value is based on log-rank test). (c) Univariate (top) and multivariate (bottom) analyses of prognostic features in the AMC-AJCCII-90 set.
Also in a multivariate analysis miR-200 promoter methylation remains an independent prognostic factor (P= 0.002).
Regulation of the mesenchymal colorectal cancer subtype
E Fessler et al
6034
Oncogene (2016) 6026 – 6037 © 2016 Macmillan Publishers Limited, part of Springer Nature.
Inference of DNA methylation regulatory network
Forty-ﬁve genes and nine miRs were selected as regulators based on two
criteria: (1) signiﬁcant inverse correlation between their expression proﬁles
and DNA methylation proﬁles (Pearson correlation coefﬁcient o − 0.5,
P-value o0.001); (2) signiﬁcant differential DNA methylation between
CMS4 and CMS1–3 samples (|log2FC|4log2(1.1), FDRo0.001). A total of
2273 genes signiﬁcantly differentially expressed between CMS4 and
CMS1–3 (|log2FC|40.5, FDRo0.001) were selected as target genes of the
total 54 regulators. Using the same approach for miR network inference,
we predicted a network representing how DNA methylation regulates
gene expression.
TCGA data
Multiple TCGA data sets were used for analyzing the correlation between
expression and promoter methylation of the miR-200 family members.
From the TCGA data portal, we obtained mRNA expression, miRNA
expression as well as DNA methylation proﬁles (all level-3 data, from 194
patients). For each miR-200 family member, we took the median β-value
over all annotated CpG sites as its promoter methylation level. The mean
methylation levels over corresponding individual miR-200 family members
were used for the miR-200ba429 and miR-200c141 clusters, respectively.
EMT heatmap
Expression of EMT-associated genes of the CIT data set was imported into
MultiExperiment Viewer (http://www.tm4.org/mev.html).6,31 Genes were
normalized by rows, median centered, and the gene tree was hierarchically
clustered using Pearson correlation.
Cells
Forty-four CRC cell lines were a kind gift from the Sanger Institute
(Cambridge, UK; authenticated by STR Genotyping). Cell lines were
mycoplasma negative, cultured in Dulbecco's modiﬁed Eagle's medium/
F-12 medium with L-glutamine, 15 mM HEPES (Thermo-Fisher Scientiﬁc,
Bleiswijk, The Netherlands), 8% fetal calf serum (Lonza, Breda, The
Netherlands), or in RPMI1640 medium with L-glutamine, 25 mM HEPES
(Thermo-Fisher Scientiﬁc), 8% fetal calf serum, 1% D-glucose solution plus
(Sigma-Aldrich, Zwijndrecht, The Netherlands) and 100 μM sodium
pyruvate (Life Technologies, Bleiswijk, The Netherlands).
Cells were plated in medium containing 0.1μM decitabine (5-aza-2′-
deoxycytidine; Sigma-Aldrich) for 96 h, 10 nM Panobinostat (LBH589;
Selleck Chemicals, Munich, Germany) for 36 h or dimethylsulfoxide.
Decitabine and dimethylsulfoxide were refreshed daily.
The primary cell lines RC511 and Co147 were derived from a colon
cancer patient as described before47 and cultured in advanced Dulbecco's
modiﬁed Eagle's medium/F-12 (Thermo-Fisher Scientiﬁc), supplemented
with N2 supplement (Invitrogen, Waltham, MA, USA), 2 mM L-glutamine,
0.15% D-glucose (Sigma-Aldrich), 100 μM β-mercaptoethanol (Sigma-
Aldrich), trace elements B and C (Thermo-Fisher Scientiﬁc), 5 mM HEPES
(Life Technologies), 2 μg/ml heparin (Sigma-Aldrich), 10 μg/ml insulin
(Sigma-Aldrich), 10 ng/ml human bFGF and 20 ng/ml human EGF
(Peprotech, London, UK) in ultra-low attachment ﬂasks (Corning, Amster-
dam, The Netherlands). Spheroids were dissociated manually and replated
in fresh medium twice weekly.
miR-200 overexpression
HUTU-80, MDST8 and NCI-H716 cells were transduced with lentiviral
particles containing lenti-miR-200b+200a+429 or lenti-miR-200c+141
(System Biosciences, Huissen, The Netherlands) constructs and sorted on
GFP after 48 h. Twenty-four hours after sorting, a fraction of the
miR-200ba429-transduced cells was transduced with miR-200c141 lenti-
virus. RNA was extracted 7 days after transduction. RC511 primary cells
were transduced with lentiviral particles containing lenti-miR-200b+200a
+429 and sorted on GFP. Two weeks after sorting, a fraction of the
miR-200ba429-transduced cells was transduced with miR-200c141
lentivirus.
For microarrays the GeneTitanTM MC system from Affymetrix (Santa
Clara, CA, USA) was used according to the standard protocols of the
Cologne Center for Genomics, University of Cologne, Germany (GEO
accession GSE65551).
Microarrays (n= 12) were ﬁrst normalized and summarized using
the robust multi-array average method.48 To identify differentially
expressed genes, one-class Rank Product analysis was employed,49 using
log2-fold changes of gene expression between each cell line over-
expressing miR-200 members and corresponding control. In the gene set
enrichment analysis,35,36 we used as phenotype the ranks of the rank
product of genes (P-values were adjusted using the Benjamini–Hochberg
method). Of the EMT signature31 only 59 genes differentially expressed
between CMS4 and CMS1–3 (|log2FC|40.85, FDRo0.001) were included.
Quantitative real-time PCR
Total RNA was extracted using the NucleoSpin miRNA kit (Macherey-Nagel,
Düren, Germany).
miRNA. One microgram of total RNA was reverse transcribed using the
HiFlex buffer of the miScript II RT Kit (Qiagen, Venlo, The Netherlands).
Quantitative real-time PCR (qRT–PCR) was performed using the miScript
SYBR Green PCR kit (Qiagen). miScript Primer assays: Hs_RNU6-2_11,
Hs_SNORA74A_11, Hs_miR-200b_3, Hs_miR-200a_1, Hs_miR-429_1,
Hs_miR-200c_1, and Hs_miR-141_1. Data shown were normalized to the
expression of SNORA74A, and normalization to RNU6-2 yielded compar-
able results.
mRNA. One microgram of total RNA was reverse transcribed using
Superscript III (Invitrogen). qRT–PCR was performed using SYBR Green and
a Roche Light Cycler 480 II (Roche, Almere, The Netherlands). Values for cell
lines were normalized to GAPDH expression; for the primary cell line RC511
values were normalized to B2M expression. Primer sequences: GAPDH-
forward: 5′-AATCCCATCACCATCTTCCA, GAPDH-reverse: 5′-TGGACTCCAC
GACGTACTCA; B2M-forward: 5′-GTCTTTCAGCAAGGACTGGTC, B2M-reverse:
5′-CTTCAAACCTCCATGATGC; ZEB1-forward: 5′-GCACAAGAAGAGCCACA
AGTA, ZEB1-reverse: 5′-GCAAGACAAGTTCAAGGGTTC; E-Cadherin-forward:
5′-TGGAGGAATTCTTGCTTTGC, E-Cadherin-reverse: 5′-CGCTCTCCTCCGAAG
AAAC; p21-forward: 5′-CAGGCTGAAGGGTCCCCA, p21-reverse: 5′-TCAGCCG
GCGTTTGGAGTGG.
miR-200 promoter methylation analysis
gDNA was extracted using the High Pure PCR Template Preparation Kit
(Roche). Two micrograms of gDNA were bisulﬁte converted using the
EpiTect Bisulﬁte Kit (Qiagen). Methylation was detected using the PyroMark
PCR system (Qiagen). PyroMark Assay Design Software 2.0 (Qiagen) was
used for primer design (miR-200ba429 promoter region: 110 basepairs (6
CpGs), miR-200c141 promoter region: 140 basepairs (11 CpGs)). Depicted is
the average methylation of all 6 or 11 CpGs combined. Primer sequences:
miR-200ba429-forward: 5′-GGTTTGAATTGATTTTTTGTGTTAGG; miR-200ba429-
reverse: 5′-CCTCAACCAAAATCAAACCTCA. miR-200ba429-sequencing primer:
5′-ATTTTTTGTGTTAGGGTTT. miR-200c141-forward: 5′-ATTGTAGAGGGGGGA
TGAG; miR-200c141-reverse: 5′-CCAAATTACAATCCAAACAAACC. miR-200c141-
sequencing primer: 5′-GATGAGGGTGGGTAA. All analyses were performed
blinded with respect to subtype and DFS data. Prior to the study, the
reproducibility of the miR-200 promoter methylation assay was tested
using control cell lines.
In vivo tumor growth
All animal experimentation was approved by the animal ethics committee
of the AMC, University of Amsterdam and the University of Palermo. In all,
100 000 primary colon cancer cells (RC511, Co149, DA13) were, after
extensive washing with phoshate-buffered saline, injected subcutaneously
into the right ﬂank of 13- to 14-week-old male NSG mice (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ, in house breeding) in 50% growth factor reduced BD
matrigel matrix (BD Biosciences, Breda, The Netherlands). Tumors were
measured twice weekly in a non-blinded way using a caliper and the
formula ‘tumor volume= (length×width2)/2’ was used to calculate the
volumes. Animals were killed when the tumor volume exceeded 1000mm3
and tumors were excised for DNA and RNA isolation. To determine the
difference in growth speed between RC511 control and RC511+miR-
200ba429+miR-200c141, group size was ﬁrst determined using a power
calculation analysis (NQuery, using a power of 80%, a conﬁdence of 0.05
and a variation estimation within the group of 20%). Based on this
calculation, six mice per group were subcutaneously injected non-
randomized, and subsequent growth and survival curves were generated
for mice over a period of 50 days (in GraphPad Prism; signiﬁcance for
survival was calculated using the log-rank test).
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Statistics
Predicted probabilities for CMS4 afﬁliation were calculated using a binary
logistic regression with miR-200ba429 and miR-200c141 methylation as
covariates for 80 patients of the AMC-AJCCII-90 data set (nine patients
could not be classiﬁed into one of the CMSs, one patient had poor gDNA
quality). The x− β values for predicting recurrence were calculated using a
Cox proportional hazards regression model with miR-200ba429 and
miR-200c141 methylation as covariates for 89 patients. The sensitivity
and speciﬁcity of CMS4 and recurrence prediction were calculated by
plotting the receiver operator characteristics curves of the predicted
probabilities and x− β values, respectively, and calculating the AUC using
IBM SPSS Statistics version 22 software (IBM, Amsterdam, The Netherlands).
Kaplan–Meier curves display survival; signiﬁcance was evaluated by log-
rank tests. DFS was measured from the day of surgery until recurrence
detection. The x− β value 0.293 was chosen to divide the patients into
methylation low (o0.293) and methylation high (40.293) (sensitivity:
68.4%, speciﬁcity: 75.7%).
Univariate and multivariate Cox proportional hazards regression models
were used to test the prognostic relevance of clinical factors and miR-200
methylation. Variables were dichotomized as follows: gender (male vs
female), age at operation (mean-dichotomized, o70.24 vs 470.24),
location (right- vs left-sided), differentiation grade (well and moderate vs
poor), T-stage (T3 vs T4), MSI vs MSS, BRAFV600E and MSS vs the rest,
miR-200ba429+miR-200c141 methylation (predicted probability of
o0.293 vs40.293). Three patients (including the patient with insufﬁcient
gDNA quality) of the AMC-AJCCII-90 data set were excluded from the uni-
and multivariate analyses for lack of differentiation grade information.
Statistics were used as indicated in the ﬁgure legends. P-values o0.05
were considered signiﬁcant (Benjamini–Hochberg-corrected, where
applicable).
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